Law360, New York (May 01, 2006, 12:00 AM ET) -- In a boon for Israeli generics maker Teva Pharmaceuticals Ltd., a federal court has ruled that its recent acquisition, Ivax Corp., should be granted 180 days of exclusivity to market a generic version of Merck & Co.’s blockbuster cholesterol drug Zocor.
Teva confirmed on Monday that it had been granted summary judgment by the U.S. District Court for the District of Columbia, triggering hopes that Ivax will finally win exclusivity following a six-year crusade to sell generic Zocor.
The development serves as welcome news for Teva,...
Court Grants Teva-Ivax Bid For Zocor Exclusivity
To view the full article, take a free trial now.
